King's Research Portal

Document Version

Publisher's PDF, also known as Version of record

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Mylona, A. (2016). Opposing effects of Elk-1 multisite phosphorylation shape its response to ERK activation. *Science*, 354(6309), 233-237.

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

SIGNAL TRANSDUCTION

Opposing effects of Elk-1 multisite phosphorylation shape its response to ERK activation

Anastasia Mylona,^{1*} Francois-Xavier Theillet,^{2†} Charles Foster,¹ Tammy M. Cheng,³ Francesc Miralles,^{1,4} Paul A. Bates,³ Philipp Selenko,² Richard Treisman^{1‡}

Multisite phosphorylation regulates many transcription factors, including the serum response factor partner Elk-1. Phosphorylation of the transcriptional activation domain (TAD) of Elk-1 by the protein kinase ERK at multiple sites potentiates recruitment of the Mediator transcriptional coactivator complex and transcriptional activation, but the roles of individual phosphorylation events had remained unclear. Using time-resolved nuclear magnetic resonance spectroscopy, we found that ERK2 phosphorylation proceeds at markedly different rates at eight TAD sites in vitro, which we classified as fast, intermediate, and slow. Mutagenesis experiments showed that phosphorylation of fast and intermediate sites promoted Mediator interaction and transcriptional activation, whereas modification of slow sites counteracted both functions, thereby limiting Elk-1 output. Progressive Elk-1 phosphorylation thus ensures a self-limiting response to ERK activation, which occurs independently of antagonizing phosphatase activity.

Multisite protein phosphorylation increases the complexity of functional signaling outputs that can be generated from single protein kinase inputs. It can set thresholds for activity or transform graded signals into switch-like responses (1–4). Many transcription factors and their interacting regulatory proteins are subject to multisite phosphorylation, which allows distinct aspects of protein function—including protein turnover, nuclear import and export, and specific protein interactions—to be

controlled independently (5). However, in general, the dynamics and functional roles of individual phosphorylation events are incompletely understood.

The ternary complex factor (TCF) subfamily of Ets-domain transcription factors, consisting of Elk-1, SAP-1, and Net, provides an example of multisite phosphorylation in transcriptional activation. TCFs, together with their partner protein SRF, function in many biological processes by coupling SRF target genes to mitogen-activated

protein kinase (MAP kinase) signaling (5). Mitogenic and stress stimuli induce phosphorylation of TCF C-terminal transcriptional activation domains (TADs) at multiple S/T-P (Ser or Thr-Pro) phosphorylation sequences, of which eight are conserved across the family (Fig. 1A and fig. S1) (6–11). Two MAP kinase docking sites, the D-box and the Phe-Gln-Phe-Pro (FQFP) motif, control phosphorylation of these sites (12–15). Multisite phosphorylation triggers transcriptional activation by TCFs, facilitating their interaction with the Mediator transcriptional coactivator complex (16–19), but the kinetics with which the different sites are phosphorylated, and whether they serve distinct functions, remain unclear.

To obtain atomic-resolution insights into phosphorylation of the Elk-1 TAD, we used nuclear magnetic resonance (NMR) spectroscopy (20) to monitor its modification by recombinant ERK2 in vitro (Fig. 1B and fig. S2A). Time-resolved NMR experiments revealed that each phosphorylation proceeded efficiently but at markedly different rates. Phosphorylation of Thr³⁶⁹ and Ser³⁸⁴, which flank the central Phe-Trp (FW) motif implicated in Mediator interaction (18), occurred faster than

Fig. 1. Multisite phosphorylation of Elk-1 TAD. (A) Linear outline of Elk-1 fast (red), intermediate (blue), and slow (yellow) S/T-P phosphorylation sites. Kinase docking motifs are shown in green; the FW residues (purple) are essential for Mediator association. (B) NMR analysis of Elk-1 TAD (amino acids 309 to 429) phosphorylation with recombinant ERK2. Left: 2D ¹H-¹⁵N NMR spectrum of unphosphorylated Elk-1 (black), with phosphorylation site signals color-coded as in (A). Right: Overlay of 2D NMR spectra of phosphorylated [gray and color-coded as in (A)] and unmodified Elk-1 (black). (C) Time-resolved modification curves of individual Elk-1 sites upon phosphorylation with ERK2; error bars denote differences between replicate experiments on two independent samples. (D) Time-course Western blot of GST-Elk-1 TAD phosphorylation and phosphorylation site-specific antibody detection.

modification of Thr³⁵⁴, Thr³⁶⁴, and Ser³⁹⁰, whereas residues Thr⁴¹⁸, Ser⁴²³, and Thr³³⁷ were modified more slowly (Fig. 1C), which we confirmed by immunoblotting (Fig. 1D). Chemical shift analysis (Ca, C β) showed no stable secondary structure elements in unmodified or phosphorylated Elk-1 TAD (fig. S2B).

As a first step toward understanding the basis for the phosphorylation sites' differential kinetic behavior, we devised a reaction model based on Michaelis-Menten enzyme kinetics. To simplify the mathematical treatment, we grouped Elk-1 sites into three classes: fast (Thr³⁶⁹ and Ser³⁸⁴), intermediate (Thr³⁵⁴, Thr³⁶⁴, and Ser³⁹⁰), and slow (Thr³³⁷, Thr⁴¹⁸, and Ser⁴²³). We assumed that ERK2 phosphorylation is distributive, that enzymatic rate constants (k_{cat}) are similar for all sites, and that the different sites have relative affinities for ERK2 modeled by increasing Michaelis-Menten constants ($K_M^{Fast} < K_M^{Int} < K_M^{Slow}$) (Fig. 2A and fig. S3A) (20). This model, which recapitulated the measured kinetics of in vitro Elk-1 phosphorylation well (Fig. 2B), predicted that removal of fast or intermediate sites should increase the phosphorylation rates of other sites. To test this idea, we analyzed the phosphorylation kinetics of Elk-1 TAD mutants in which we substituted all fast or intermediate phosphoacceptor residues with alanines (Elk-1F: Thr³⁶⁹ → Ala, Ser³⁸⁴ → Ala; Elk-1I: Thr³⁵⁴ → Ala, Thr³⁶⁴ → Ala, Ser³⁹⁰ → Ala) (Fig. 2A). In the fast-site mutant Elk-1F, phosphorylation rates of intermediate and slow sites increased, whereas those of the fast and slow sites increased in the intermediate-site mutant Elk-1I; in both cases, the altered kinetics fit well with those predicted by the model (Fig. 2B and fig. S3B). Thus, even the fast sites are not phosphorylated at the maximum possible rate in the wild-type protein. Moreover, phosphorylation of an Elk-1 TAD mutant in which Thr³⁶⁹ and Ser³⁸⁴ were replaced with aspartates was similar to Elk-1F, excluding the possibility that fast-site phosphorylation primes later modification events (fig. S3B).

To gain more insight into the factors affecting individual sites' phosphorylation kinetics, we assessed the role played by primary sequence. To do this, we exchanged the sequences surrounding the fast Thr³⁶⁹ and slow Ser⁴²³ sites. This also effectively exchanged their reactivities, which suggests that these sites' phosphorylation rates reflect their position relative to ERK docking sequences, rather than intrinsic differences in reactivity (Fig. 2C). We therefore examined the contributions of the D-box and FQFP ERK docking motifs to each site's phosphorylation kinetics. Deletion of the D-box decreased the rates of Thr³³⁷, Thr³⁵⁴, Thr³⁶⁴, and Thr³⁶⁹ phosphorylation but increased the rates of Ser³⁹⁰, Thr⁴¹⁸, and Ser⁴²³ modification (Fig. 2D). In contrast, deletion of the FQFP motif decreased the rate of Ser³⁸⁴ phosphorylation but enhanced modification of intermediate sites, including adjacent Ser³⁹⁰, with no effect on the C-terminal sites (Fig. 2D). Thus, the ERK docking motifs differentially affect each phosphorylation site's competitive behavior. Previous studies showed that Elk-1 TAD phosphorylation by JNK and p38

Fig. 2. Phosphorylation kinetics of Elk-1 TAD mutants. (A) Outline of analyzed Elk-1 TAD mutants. Substrate sites were classified as fast (red), intermediate (blue), or slow (yellow) for model calculations. (B) Left: Comparison of averaged measured data points of wild-type Elk-1 TAD fast-, intermediate-, and slow-site phosphorylation by ERK2 (circles) with calculated rates according to the competitive inhibition model (solid lines). Center: Fast-site alanine-substituted Elk-1 TAD (Elk-1F); dashed lines show wild-type Elk-1 TAD for comparison. Right: Intermediate-site alanine-substituted Elk-1 TAD (Elk-1I); dashed lines show wild-type Elk-1 TAD for comparison. (C) Time-resolved modification curves (right) of the Elk-1 369/423 switch mutant (left). Amino acid abbreviations: G, Gly; K, Lys; L, Leu; P, Pro; Q, Gln; S, Ser; T, Thr; V, Val. Error bars denote differences between replicate experiments on two independent samples. (D) Time-resolved modification curves of ERK docking-site mutants Elk-1ΔD-box (left) and Elk-1ΔFQFP (right), presented as in (C). Effects of D-box and FQFP site deletions on Elk-1 TAD phosphorylation rates are summarized below.

MAP kinases differs from phosphorylation by ERK (10, 21–24) and that this reflects differences in their docking interactions (12, 14, 15, 25). In-

deed, these kinases exhibited site preferences and phosphorylation rates that were distinct from that of ERK2 (fig. S3C). Taken together,

Fig. 3. Effects of Elk-1 TAD mutations on TCF target gene expression, cell proliferation, and Mediator binding. (A) Quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis of TCF target gene transcription in reconstituted TKO MEFs. Cells were reconstituted with wild-type mouse Elk-1 (WT) or fast-site (F), intermediate-site (I), slow-site (S), fast- and intermediate-site (FI), or alanine-substituted FW motif (FW) mutants. (B) Effects of individual slow-site alanine substitutions on *Egr1* expression. Data are expressed relative to expression of GAPDH. In (A) and (B), cells were stimulated with TPA (50 ng/ml)

where indicated. RNA levels are quantified relative to GAPDH; data are means $\pm$ SEM, $n = 3$. (C) Proliferation of wild-type and mutant Elk-1 TKO MEFs. Data are means $\pm$ SEM, $n = 3$. (D) Coimmunoprecipitation of Mediator with wild-type or mutant Flag-tagged Elk-1 from NIH3T3 cell extracts. Antibodies to Mediator subunits MED23, MED24, and MED16 were used for immunoblotting. (E) Mediator coprecipitation from unstimulated NIH3T3 cell extracts using wild-type and mutant GST-tagged Elk-1 TAD proteins with and without prior ERK2 phosphorylation.

our results show that the different rates of Elk-1 TAD phosphorylation by ERK2 follow a competition mechanism that is governed by the position of individual Elk-1 substrate sites relative to ERK2 docking interactions.

To test whether the different kinetic classes of Elk-1 TAD phosphorylation sites are functionally equivalent, we expressed Elk-1 mutants in fibroblasts derived from TCF-deficient (*Elk1*^{-/-}; *Elk3*^{8/8}; *Elk4*^{-/-}) triple-knockout mouse embryos (TKO MEFs; fig. S4, A to C). In these cells, immediate-early (IE) gene expression is defective, but expression of wild-type mouse Elk-1 restored the IE transcriptional activation seen in wild-type MEFs after activation of ERK by treatment with TPA (12-*O*-tetradecanoylphorbol-13-acetate) (fig. S4D). As expected, alanine substitutions of fast and/or intermediate sites, or of the FW motif, greatly diminished or abolished the ability of Elk-1 to activate TCF-SRF target gene transcription after TPA stimulation (Fig. 3A). Surprisingly, however, mutation of the slow sites substantially enhanced Elk-1-mediated activation of TCF-SRF target genes (Fig. 3A). Alanine substitutions at

individual slow sites also increased Elk-1 activity, with Thr⁴¹⁸ exhibiting the greatest effect (Fig. 3B and fig. S4, E to G). TCF-SRF signaling is important for cellular proliferation (26, 27), and TKO MEFs proliferated more slowly than wild-type MEFs. The reconstituted TKO MEFs exhibited enhanced proliferation rates, which correlated with the ability of each mutant to promote transcriptional activation (Fig. 3C).

Phosphorylation of Elk-1 promotes transcriptional activation by facilitating its MED23-dependent interaction with the Mediator complex (16–18). We therefore investigated whether the different transcriptional activities of the Elk-1 mutants reflected alterations in Mediator binding. We prepared extracts of TKO cells expressing wild-type or mutant Elk-1 proteins and assessed Elk-1 association with Mediator by coimmunoprecipitation of the MED23, MED24, and MED16 subunits. Consistent with the transcription experiments, Elk-1–Mediator interaction was induced by TPA stimulation and dependent on the FW motif; it was abolished by alanine substitutions of fast and intermediate sites, and increased in the slow-site Elk-1 mutant

(Fig. 3D). We obtained similar results when we used glutathione *S*-transferase (GST)–Elk-1 TAD proteins to recover Mediator proteins from unstimulated NIH3T3 cell extracts (Fig. 3E). In this assay, ERK2 phosphorylation time-course experiments showed that Mediator recovery by the wild-type Elk-1 TAD was most efficient prior to modifications of the slow sites (fig. S5, A and B). Taken together, these data show that according to the sites involved, ERK2 phosphorylation promotes or inhibits transcriptional activation by Elk-1, which reflects alterations in Elk-1–Mediator interactions.

Next, we investigated Elk-1 TAD phosphorylation kinetics in vivo. Previous studies were unable to distinguish the progressive phosphorylation of fast and slow Elk-1 sites (6). However, by incubating cells at 25°C to slow down reactions, we confirmed that phosphorylation rates can be ranked in the order Ser³⁸⁴ > Thr³⁶⁴ > Thr⁴¹⁸ and that different site classes exhibited a similar competitive behavior, as seen in vitro (fig. S6A). Reasoning that phosphorylation of the Elk-1 TAD might be sensitive to kinetic effects at limiting signal strengths, we titrated ERK activity using

Fig. 4. Multisite phosphorylation of Elk-1 shapes the transcriptional response to ERK activation.

(**A**) Kinetics of Elk-1 fast- and slow-site phosphorylation in cells treated with increasing concentrations of TPA. (**B**) Transcription rate of the TCF-SRF target gene *Egr1* in TKO MEFs expressing wild-type Elk-1 or mutant Elk-1S. Precursor RNA was monitored by qRT-PCR after stimulation with different concentrations of TPA. Data are means $\pm$ SEM; $n = 3$. (**C**) Kinetics of *Egr1* mRNA accumulation in cells as in (**B**) monitored by qRT-PCR. (**D**) Progressive Elk-1 phosphorylation by ERK has both activating (left and center) and inhibitory (right) effects on Mediator recruitment, as suggested by shading densities. A strong signal will rapidly reach the attenuated state shown at the right; a weak signal may reach this state only if sustained.

increasing amounts of TPA. This both increased the maximal extent of ERK activation and advanced the time at which it occurred (fig. S6B). At low TPA concentrations, Elk-1 fast-site (Ser³⁸⁴) and slow-site (Thr⁴¹⁸) modifications accumulated slowly over 1 hour, whereas at a saturating TPA dose they were maximal by 10 min. Both phosphorylations declined at late times, presumably owing to the action of Elk-1 phosphatases (Fig. 4A) (6, 28).

Having established that Elk-1 phosphorylation kinetics are tuned by signal strength, we

investigated their relationship to transcriptional activation. We compared the ability of wild-type Elk-1 and the slow-site mutant Elk-1S to activate transcription in response to signals of differing strengths. At saturating TPA concentrations, both proteins activated *Egr1* transcription with similar transient kinetics, although Elk-1S was much more active, reflecting the loss of the inhibitory sites (Fig. 4, B and C). At limiting TPA doses, however, their behaviors were markedly different. Whereas the activity of wild-type Elk-1 was almost

maximal by 15 min, that of Elk-1S increased substantially beyond this time (Fig. 4B), resulting in prolonged *Egr1* mRNA accumulation (Fig. 4C). Thus, progressive phosphorylation of the Elk-1 TAD by a single kinase, ERK, attenuates the transcriptional response of Elk-1, shaping it according to the strength and kinetics of ERK activation.

Our results show that phosphorylation of the Elk-1 TAD by ERK can either promote or inhibit Mediator interaction depending on the sites involved, thereby modulating transcriptional activation. Given that the TAD sequences are conserved in the other TCFs, our findings may also apply to them. The more rapidly phosphorylated sites are located in the substantially conserved central core of the TAD and are essential for transcriptional activation, lying close to the FW hydrophobic motif required for Elk-1-Mediator interaction (10, 18). Multisite phosphorylation of these residues might stabilize this interaction and perhaps also set a signaling threshold for it, similar to the way that multisite phosphorylation sets a threshold for the Sic1-Cdc4 interaction (29). In contrast, slowly phosphorylated sites located N- and C-terminal of the conserved TAD core act negatively. Their phosphorylation inhibits Mediator recruitment and limits transcriptional activation (Fig. 4D) and may also facilitate recruitment of negative regulators of Elk-1 activity. Together, these properties ensure that ERK phosphorylation of the Elk-1 TAD is self-limiting, whereby phosphorylation of slow sites attenuates TCF-SRF target gene expression under conditions of strong or sustained ERK signaling (Fig. 4D). Our results challenge the common assumption that multisite modification events act unidirectionally and can only be reversed or limited by antagonistic enzymes, such as phosphatases. Given the prevalence of such events in different biological processes, we expect that similar mechanisms may govern other regulatory interactions.

REFERENCES AND NOTES

1. J. Gunawardena, *Proc. Natl. Acad. Sci. U.S.A.* **102**, 14617–14622 (2005).
2. J. Gunawardena, *Biophys. J.* **93**, 3828–3834 (2007).
3. C. Salazar, T. Höfer, *FEBS J.* **276**, 3177–3198 (2009).
4. X. Liu, L. Bardwell, Q. Nie, *Biophys. J.* **98**, 1396–1407 (2010).
5. M. Karin, T. Hunter, *Curr. Biol.* **5**, 747–757 (1995).
6. F. H. Cruzalegui, E. Cano, R. Treisman, *Oncogene* **18**, 7948–7957 (1999).
7. R. Janknecht, W. H. Ernst, V. Pingoud, A. Nordheim, *EMBO J.* **12**, 5097–5104 (1993).
8. R. Marais, J. Wynne, R. Treisman, *Cell* **73**, 381–393 (1993).
9. R. Janknecht, W. H. Ernst, A. Nordheim, *Oncogene* **10**, 1209–1216 (1995).
10. M. A. Price, A. E. Rogers, R. Treisman, *EMBO J.* **14**, 2589–2601 (1995).
11. H. Gille et al., *EMBO J.* **14**, 951–962 (1995).
12. D. A. Fantz, D. Jacobs, D. Glossip, K. Kornfeld, *J. Biol. Chem.* **276**, 27256–27265 (2001).
13. S. H. Yang, P. R. Yates, A. J. Whitmarsh, R. J. Davis, A. D. Sharrocks, *Mol. Cell. Biol.* **18**, 710–720 (1998).
14. S. H. Yang, A. J. Whitmarsh, R. J. Davis, A. D. Sharrocks, *EMBO J.* **17**, 1740–1749 (1998).
15. D. Jacobs, D. Glossip, H. Xing, A. J. Muslin, K. Kornfeld, *Genes Dev.* **13**, 163–175 (1999).
16. J. L. Stevens et al., *Science* **296**, 755–758 (2002).
17. G. Wang et al., *Mol. Cell* **17**, 683–694 (2005).
18. M. A. Balamotis et al., *Sci. Signal.* **2**, ra20 (2009).

19. W. Wang *et al.*, *Dev. Cell* **16**, 764–771 (2009).
20. F. X. Theillet *et al.*, *Nat. Protoc.* **8**, 1416–1432 (2013).
21. M. Cavigelli, F. Dolfi, F. X. Claret, M. Karin, *EMBO J.* **14**, 5957–5964 (1995).
22. H. Gille, T. Strahl, P. E. Shaw, *Curr. Biol.* **5**, 1191–1200 (1995).
23. A. J. Whitmarsh, P. Shore, A. D. Sharrocks, R. J. Davis, *Science* **269**, 403–407 (1995).
24. M. A. Price, F. H. Cruzalegui, R. Treisman, *EMBO J.* **15**, 6552–6563 (1996).
25. D. L. Sheridan, Y. Kong, S. A. Parker, K. N. Dalby, B. E. Turk, *J. Biol. Chem.* **283**, 19511–19520 (2008).
26. E. R. Vickers *et al.*, *Mol. Cell. Biol.* **24**, 10340–10351 (2004).
27. M. A. Wozniak *et al.*, *Curr. Biol.* **22**, 2017–2026 (2012).
28. T. Sugimoto, S. Stewart, K. L. Guan, *J. Biol. Chem.* **272**, 29415–29418 (1997).
29. P. Nash *et al.*, *Nature* **414**, 514–521 (2001).

ACKNOWLEDGMENTS

Work in the Treisman group was supported by the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001-190), the UK Medical Research Council (FC001-190), and the Wellcome Trust (FC001-190), and by European Research Council (ERC) advanced grant 268690 ACTINonSRF. Work in the Selenko group is funded by ERC consolidator grant 647474 NeuroInCellNMR. F.-X.T. is supported by Agence Nationale pour la Recherche grant ANR14-ACHN-0015-01. The authors have no conflicts of interest. Author contributions: A.M. conceived the project; A.M., C.F., and F.M. designed and performed molecular and cell biology experiments; F.-X.T., T.M.C., and P.A.B. developed the competitive inhibition model; F.-X.T. and P.S.

designed, executed, and interpreted the NMR experiments; and A.M., P.S., and R.T. designed and interpreted experiments and wrote the paper. We thank F. Gualdrini, C. Esnault, and P. Costello for characterizing gene regulation in reconstituted TKO MEFs, sharing their unpublished data, and generating reconstituted TKO MEF cells; the Crick Genomics and Flow Cytometry technology platforms for technical support; and A. Behrens, V. Calleja, A. Chakraborty, M. Diefenbacher, C. Duellberg, R. Nicolas, P. Riou, M. Skehel, and our group members for advice and discussions.

SUPPLEMENTARY MATERIALS

www.sciencemag.org/content/354/6309/233/suppl/DC1
Figs. S1 to S6
References (30–41)

5 August 2015; accepted 23 August 2016
10.1126/science.aad1872

VACCINES

Rapid development of a DNA vaccine for Zika virus

Kimberly A. Dowd,^{1*} Sung-Youl Ko,^{2*} Kaitlyn M. Morabito,² Eun Sung Yang,² Rebecca S. Pelc,¹ Christina R. DeMaso,¹ Leda R. Castillo,^{2,3} Peter Abbink,⁴ Michael Boyd,⁴ Ramya Nityanandam,⁴ David N. Gordon,¹ John Robert Gallagher,⁵ Xuejun Chen,² John-Paul Todd,² Yaroslav Tsybovsky,⁶ Audray Harris,⁵ Yan-Jang S. Huang,⁷ Stephen Higgs,⁷ Dana L. Vanlandingham,⁷ Hanne Andersen,⁸ Mark G. Lewis,⁸ Rafael De La Barrera,⁹ Kenneth H. Eckels,⁹ Richard G. Jarman,¹⁰ Martha C. Nason,¹¹ Dan H. Barouch,⁴ Mario Roederer,² Wing-Pui Kong,² John R. Mascola,² Theodore C. Pierson,^{1†} Barney S. Graham^{2†}

Zika virus (ZIKV) was identified as a cause of congenital disease during the explosive outbreak in the Americas and Caribbean that began in 2015. Because of the ongoing fetal risk from endemic disease and travel-related exposures, a vaccine to prevent viremia in women of childbearing age and their partners is imperative. We found that vaccination with DNA expressing the premembrane and envelope proteins of ZIKV was immunogenic in mice and nonhuman primates, and protection against viremia after ZIKV challenge correlated with serum neutralizing activity. These data not only indicate that DNA vaccination could be a successful approach to protect against ZIKV infection, but also suggest a protective threshold of vaccine-induced neutralizing activity that prevents viremia after acute infection.

The emergence of Zika virus (ZIKV) in the Americas and Caribbean follows a series of global threats to public health from mosquito-borne viral diseases over the past three decades. Because of the profound impact on individuals and society from a disabling congenital disease caused by ZIKV infection in pregnant women, the World Health Organization declared ZIKV a global health emergency in February 2016. Although it is likely that the incidence of ZIKV infection will decline considerably within 1 to 2 years (1), it is also likely that ZIKV will become endemic in tropical and subtropical regions, with sporadic outbreaks and potential for spread into new geographical areas, as observed with other emerging arboviruses such as West Nile (WNV) and chikungunya. Therefore, unless immunity is established before childbearing age, pregnant women will continue to be at risk for an infection that could harm their fetus. Further, because men can harbor ZIKV in semen for several months after a clinically unapparent

infection and can sexually transmit virus to a pregnant partner (2), even women in nonendemic regions will have some ongoing risk if exposed to men who have traveled to endemic regions. These characteristic features of transmission and disease suggest that there will be an ongoing need for a ZIKV vaccine to maintain a high level of immunity in the general population and in travelers to endemic regions to reduce the frequency of fetal infection.

To rapidly address the critical need for a preventive vaccine to curtail the ongoing ZIKV outbreak in the Americas, we chose a gene-based vaccine delivery approach that leverages our prior experience with a DNA-based WNV vaccine (3). Advantages of DNA vaccines include the ability to rapidly test multiple candidate antigen designs, the ability to rapidly produce material that conforms to good manufacturing practices, an established safety profile in humans, and a relatively straightforward regulatory pathway into clinical evaluation.

Antigen design was guided by prior knowledge about humoral immunity to flaviviruses. Vaccine-

elicited neutralizing antibodies (NAbs) are associated with protection from flavivirus-mediated disease (4). Because the most potent monoclonal flavivirus NAbs map to conformational epitopes in domain III (DIII) of the envelope (E) protein (5), or to more complex quaternary epitopes that bridge between antiparallel E dimers or between dimer rafts arrayed on the virus surface (6, 7), our goal was to identify constructs that produced particles that faithfully captured the antigenic complexity of infectious virions. Expression of the structural proteins premembrane (prM) and E are sufficient for the production and release of virus-like subviral particles (SVPs) with antigenic and functional properties similar to those of infectious virions (8, 9).

To identify promising vaccine candidates, prM-E constructs were synthesized and screened for expression and efficiency of particle release from transfected cells. prM-E sequences were inserted into a cytomegalovirus immediate early promoter-containing vector (VRC8400) that has been evaluated clinically in several previous studies (3, 10, 11). These constructs are distinct from one reported in recent studies by Larocca *et al.* (12) and Abbink *et al.* (13) that was based on a Brazilian isolate (strain

¹Viral Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. ²Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. ³Federal University of Rio de Janeiro, COPPE (Instituto Alberto Luiz Coimbra de Pós-Graduação e Pesquisa de Engenharia), Chemical Engineering Program, Rio de Janeiro, Rio de Janeiro, Brazil. ⁴Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. ⁵Structural Informatics Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. ⁶Electron Microscopy Laboratory, Cancer Research Technology Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA. ⁷Department of Diagnostic Medicine/Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506, USA. ⁸Bioqual, Rockville, MD 20852, USA. ⁹Translational Medicine Branch, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA. ¹⁰Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA. ¹¹Biostatistics Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20852, USA.

*These authors contributed equally to this work. †Corresponding author. Email: piersonc@niaid.nih.gov (T.C.P.); bgraham@mail.nih.gov (B.S.G.)

Opposing effects of Elk-1 multisite phosphorylation shape its response to ERK activation

Anastasia Mylona, Francois-Xavier Theillet, Charles Foster, Tammy M. Cheng, Francesc Miralles, Paul A. Bates, Philipp Selenko and Richard Treisman (October 13, 2016)

Science **354** (6309), 233-237. [doi: 10.1126/science.aad1872]

Editor's Summary

A function for multisite phosphorylation

Many transcription factors are regulated by phosphorylation on multiple residues. Mylona *et al.* analyzed multisite phosphorylation in the transcription factor Elk-1 and showed that it may protect against excessive activation (see the Perspective by Whitmarsh and Davis). Phosphorylation by the kinase ERK2 occurred at eight sites, but the sites were phosphorylated at different rates. Those that were phosphorylated more quickly promoted transcriptional activation. Those that were phosphorylated more slowly dampened excessive activation by ERK2s without needing a phosphatase or any other negative regulatory component.

Science, this issue p. 233; see also p. 179

This copy is for your personal, non-commercial use only.

Article Tools

Visit the online version of this article to access the personalization and article tools:

<http://science.sciencemag.org/content/354/6309/233>

Permissions

Obtain information about reproducing this article:

<http://www.sciencemag.org/about/permissions.dtl>

Science (print ISSN 0036-8075; online ISSN 1095-9203) is published weekly, except the last week in December, by the American Association for the Advancement of Science, 1200 New York Avenue NW, Washington, DC 20005. Copyright 2016 by the American Association for the Advancement of Science; all rights reserved. The title *Science* is a registered trademark of AAAS.